RIL
AKBA icon

Rothschild Investment LLC’s Akebia Therapeutics AKBA Stock Holding History

Rothschild Investment LLC’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228 Buy
164
+163
+16,300% +$224 ﹤0.01% 3281
2025
Q4 		$2 Sell
1
-389
-100% -$814 ﹤0.01% 3418
2025
Q3 		$1.06K Sell
390
-200
-34% -$665 ﹤0.01% 2545
2025
Q2 		$2.15K Buy
590
+485
+462% +$1.33K ﹤0.01% 2029
2025
Q1 		$202 Buy
+105
New +$214 ﹤0.01% 2847

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rothschild Investment LLC's AKBA Position: Q1 2026 in Review

Rothschild Investment LLC increased its Akebia Therapeutics (AKBA) stake by 16,300% in Q1 2026, buying an estimated $224 and bringing the position to 164 shares worth $228. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

Rothschild Investment LLC first reported a position in AKBA in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.15K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Rothschild Investment LLC held 164 shares of Akebia Therapeutics worth $228 as of Q1 2026.
  • Rothschild Investment LLC bought 163 Akebia Therapeutics shares in Q1 2026, an estimated $224.
  • Akebia Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3281 holding.
  • Rothschild Investment LLC first reported a position in Akebia Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Rothschild Investment LLC's Akebia Therapeutics position peaked at $2.15K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.